Monday, November 16, 2026 | 01:56 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Page 12 - Q3 Results

GIC Re Q3 result: Profit falls 6% to ₹1,519 cr; income rises to ₹11,557 cr

GIC Re on Saturday reported a 6 per cent drop in net profit to Rs 1,519 crore for the third quarter ended December 2025. The state-owned reinsurance company earned a net profit of Rs 1,621 crore in the October-December period of the last fiscal. Total income of the re-insurer rose to Rs 11,557 crore in the quarter, compared to Rs 10,479 crore in the same quarter a year ago, GIC Re said in a regulatory filing. Gross premium improved to Rs 10,987 crore during the third quarter of the current fiscal against Rs 9,968 crore a year ago period. During the quarter, the premium earned rose to Rs 9,580 crore, as against Rs 8,540 crore in the same period a year ago. The solvency ratio increased to 3.87 from 3.52 at the end of December 2024. Total assets of the company rose to Rs 2,03,414 crore, as against Rs 1,88,953 crore in the same period of previous year. GIC Re is the largest reinsurer in the domestic reinsurance market and leads most of the domestic companies' treaty programmes and .

GIC Re Q3 result: Profit falls 6% to ₹1,519 cr; income rises to ₹11,557 cr
Updated On : 07 Feb 2026 | 10:32 PM IST

SBI Q3FY26 results: Net profit up 24.5% to ₹21,028 crore on strong NII

SBI's Q3FY26 net profit rose 24.5 per cent to ₹21,028 crore on higher NII and non-interest income. The bank raised FY26 credit growth guidance to 13-15 per cent

SBI Q3FY26 results: Net profit up 24.5% to ₹21,028 crore on strong NII
Updated On : 07 Feb 2026 | 6:01 PM IST

SBI Q3FY26 result: Profit jumps 13.06% to ₹21,317 cr, income at ₹1.85 trn

On a standalone basis, the largest lender in the country reported 24.48 per cent jump in the December quarter net profit at ₹21,028 crore as against ₹16,891 crore in the year-ago period

SBI Q3FY26 result: Profit jumps 13.06% to ₹21,317 cr, income at ₹1.85 trn
Updated On : 07 Feb 2026 | 2:53 PM IST

Q3 results: SBI, Mahanagar Gas, Chemplast Sanmar among 109 firms on Feb 7

Q3FY26 company results: Firms including Tinna Rubber and Infrastructure, Autoline Industries, Balkrishna Paper Mills, and VST Tillers Tractors are also to release their October-December earnings today

Q3 results: SBI, Mahanagar Gas, Chemplast Sanmar among 109 firms on Feb 7
Updated On : 07 Feb 2026 | 10:44 AM IST

Tata Steel Q3FY26 results: Profit surges 723%, revenue increases 6%

Gains come on the back of higher India volumes, Netherlands turnaround

Tata Steel Q3FY26 results: Profit surges 723%, revenue increases 6%
Updated On : 06 Feb 2026 | 11:01 PM IST

JK Tyre and Industries posts record revenue of ₹4,223 crore in Q3FY26

JK Tyre reported its highest-ever quarterly revenue in Q3 FY26 as volumes recovered and raw material costs eased, helping profits rebound sharply from a weak base last year

JK Tyre and Industries posts record revenue of ₹4,223 crore in Q3FY26
Updated On : 06 Feb 2026 | 10:39 PM IST

Tata Motors PV: Analysts cautiously positive despite Q3 loss, JLR headwinds

Tata Motors Q3FY26 results: Analysts stay cautiously positive as India PV growth improves, JLR outlook stabilises. Targets range ₹310-₹460.

Tata Motors PV: Analysts cautiously positive despite Q3 loss, JLR headwinds
Updated On : 06 Feb 2026 | 10:38 PM IST

NSE Q3 PAT drops 37% to ₹2,409 crore, IPO committee reconstituted

Transaction charges, which constitute over two-thirds of the total income, fell 12 per cent Y-o-Y. The decline likely reflects lower trading volumes and market activity

NSE Q3 PAT drops 37% to ₹2,409 crore, IPO committee reconstituted
Updated On : 06 Feb 2026 | 8:36 PM IST

Tata Steel Q3FY26 profit jumps multifold to ₹2,688.7 cr, revenue up 6.4%

Surge in Tata Steel's Q3 profit comes on the back of improving profit margin, which rose to 4.79 per cent in Q3FY26, from 0.55 per cent in the same quarter last year

Tata Steel Q3FY26 profit jumps multifold to ₹2,688.7 cr, revenue up 6.4%
Updated On : 06 Feb 2026 | 6:44 PM IST

JM Financial Q3FY26 results: Net profit jumps 50% to ₹313 crore

JM Financial Ltd has reported a 50 per cent jump in its consolidated profit after tax of Rs 313 crore for the third quarter ended December 2025, driven by strong performance in its corporate advisory, capital markets and private business segments. The company had posted a profit after tax (PAT) of Rs 209 crore in the same period of the last year, the Mumbai-based company said in a regulatory filing on Thursday. For the nine months ended December 2025, JM Financial's PAT jumped 69 per cent year-on-year to Rs 1,037 crore, it added. Fees and commission income increased by 32 per cent to Rs 306 crore, while operating PAT rose 17 per cent to Rs 244 crore. Its consolidated net worth stood at Rs 10,418 crore, up 17 per cent. Vishal Kampani, Vice Chairman and Managing Director, JM Financial Ltd, said the company crossed Rs 1,000 crore in PAT during the first nine months, with strong execution of strategies across businesses. "Private Markets, which provides a natural hedge to volatility i

JM Financial Q3FY26 results: Net profit jumps 50% to ₹313 crore
Updated On : 06 Feb 2026 | 4:27 PM IST

Goodyear India, MRF surge up to 16% after strong Q3 result

Volume growth of tyre companies remained healthy, supported by robust momentum in both the OEM and replacement segments, along with continued premiumisation, said Ceat management.

Goodyear India, MRF surge up to 16% after strong Q3 result
Updated On : 06 Feb 2026 | 3:06 PM IST

Jubilant Pharmova shares fall over 4% after Q3 net profit declines 17% YoY

Jubilant Pharmova shares: The scrip fell as much as 4.4 per cent to ₹931 per share on the National Stock Exchange (NSE)

Jubilant Pharmova shares fall over 4% after Q3 net profit declines 17% YoY
Updated On : 06 Feb 2026 | 2:36 PM IST

MRF Q3FY26 result: Profit more than doubles to ₹692 cr, dividend declared

MRF's Q3 revenue from operations increased 15 per cent Y-o-Y to ₹8,050.43 crore from ₹7,000.82 crore in Q3FY25. Sequentially, revenue was up 9.1 per cent from ₹7,378.72 crore in Q2FY26

MRF Q3FY26 result: Profit more than doubles to ₹692 cr, dividend declared
Updated On : 06 Feb 2026 | 2:19 PM IST

Physicswallah falls 4% after Q3 results; 20% down from IPO listing price

Physicswallah had reported a 33 per cent year-on-year (Y-o-Y) increase in its net profit to 102.3 crore compared to ₹76.7 crore in the year-ago period

Physicswallah falls 4% after Q3 results; 20% down from IPO listing price
Updated On : 06 Feb 2026 | 2:19 PM IST

AAVAS Financiers hits 52-week low, stock slips 7% post Q3 results

AAVAS Financiers stock quoted lower for the eight straight trading day, and has plunged 14 per cent during this period.

AAVAS Financiers hits 52-week low, stock slips 7% post Q3 results
Updated On : 06 Feb 2026 | 1:35 PM IST

Bharti Hexacom share price jumps 6% as Q3 net profit rises 82% YoY

The stock rose as much as 6.2 per cent to ₹1,729, the highest level since January 12 on the National Stock Exchange (NSE)

Bharti Hexacom share price jumps 6% as Q3 net profit rises 82% YoY
Updated On : 06 Feb 2026 | 1:31 PM IST

Sai Life Sciences shares jump 8% as Q3 profit surges 86% YoY

Sai Life Sciences has invested ₹405 crore in capital expenditure so far, against its planned outlay of ₹700 crore for FY26

Sai Life Sciences shares jump 8% as Q3 profit surges 86% YoY
Updated On : 06 Feb 2026 | 12:49 PM IST

Alembic Pharma shares slide 4% on Q3 profit miss; is it a good time to buy?

Alembic Pharma shares today: Analysts at Motilal Oswal Financial Services (MOFSL) have retained their Neutral rating on Alembic Pharma, with a target price of ₹860 per share

Alembic Pharma shares slide 4% on Q3 profit miss; is it a good time to buy?
Updated On : 06 Feb 2026 | 11:22 AM IST

Nykaa rises 4% to 1-mth high on Q3 result; analysts hike target price

The scrip increased as much as 4.1 per cent to ₹271.80, the highest level since January 5 on the National Stock Exchange (NSE)

Nykaa rises 4% to 1-mth high on Q3 result; analysts hike target price
Updated On : 06 Feb 2026 | 11:05 AM IST

Alembic to skip first wave of global semaglutide launches, eyes India

Alembic Pharmaceuticals said it will miss the first wave of global generic semaglutide launches but is exploring partnerships for a faster entry into the Indian market

Alembic to skip first wave of global semaglutide launches, eyes India
Updated On : 06 Feb 2026 | 10:42 AM IST